PHARMACEUTICAL
manufacturer Merck & Co has
reported a US$752 million dollar
dip in its second quarter net income
to US$752.4 million from US$1.56
billion in the corresponding period
last year.
Sales for the quarter however
were up to US$11.35b from
US$5.9b in 09.
Merck blamed its poorer-thanexpected
performance on costs
associated with restructuring
changes incurred through its buyout
of the Schering Plough
Corporation, as well as patent
expiries and a “challenging economy”.
The results have also prompted
Merck to review its full year profit
forecast, putting it between
US$45.4b and US$46.1b, down
US$300m from its April outlook.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Aug 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.